New combo therapy aims to tame stage IV lung cancer
NCT ID NCT03223155
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is for people with stage IV non-small cell lung cancer. It tests whether giving targeted radiation before or at the same time as two immunotherapy drugs (nivolumab and ipilimumab) is safe. The goal is to find the best radiation dose for different tumor locations while limiting side effects. About 78 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Genetic roadmaps for advanced cancer: study tests whether expert navigation boosts targeted therapy use
- Could a cancer drug fight the wasting away seen in advanced lung cancer?
- Targeted drug shows promise for Gene-Driven lung cancers
- Gene-Hacked immune cells take on tough cancers
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy
- New radiation approach targets multiple tumors at once in early trial